Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.


BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in disease-free survival (DFS) and DFS-associated factors between patients receiving lobectomy and surgeons' preference sublobar resection were analyzed after 1-1 propensity score-matching (n = 119 per group). RESULTS:In total, 1064 pathological stage I NSCLC patients were identified, including 816 (76.7%) who underwent lobectomy, 111 (10.4%) who underwent sublobar resection as a compromised procedure (medically unfit), and 137 (12.9%) who underwent surgeons' preference sublobar resection. Rates of five-year DFS for patients undergoing lobectomy, medically unfit, and surgeons' preference sublobar resection were 88.7%, 71.0%, and 93.4%, respectively (P < 0.001). Multivariable Cox regression analysis demonstrated that radiological solid-appearance (adjusted hazard [aHR] = 2.908, P = 0.003), PL2 invasion (aHR = 1.970, P = 0.024), and angiolymphatic invasion (aHR = 2.202, P = 0.005) were significantly associated with lower DFS after adjusting for surgeons' preference sublobar resection (aH = 1.031, P = 0.939). Subgroup analysis of all 403 solid-dominant patients demonstrated equivalent five-year DFS between surgeons' preference sublobar resection and lobectomy (87.7% and 84.1%, respectively, P = 0.721). Propensity-matched analysis showed no differences in five-year DFS in stage I NSCLC patients undergoing lobectomy or surgeons' preference sublobar resection (90.5% vs. 93.4% P = 0.510), and DFS for surgeons' preference sublobar resection remained an insignificant factor (aHR = 0.894, P = 0.834). CONCLUSIONS:Carefully selected patients who have undergone surgeons' preference sublobar resection have comparable outcomes to those receiving lobectomy for stage I NSCLC <3 cm. KEY POINTS:Significant findings of the study Intended sublobar resection has a good outcome. What this study adds Sublobar resection is applicable for stage I NSCLC <3 cm.


Thorac Cancer


Thoracic cancer


Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS




Has Abstract


2020-04-01 00:00:00












  • A nurse-driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery.

    abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

    更新日期:2020-04-01 00:00:00

  • Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis.

    abstract:BACKGROUND:Radiofrequency ablation and microwave ablation are frequently prescribed for thoracic cancer. However, few writers have been able to draw on any systematic research into the differences between the two ablation methods. METHODS:A literature search was carried out using Embase, PUBMED, Web of Science, Cochra...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,多中心研究


    authors: Sun YD,Zhang H,Liu JZ,Xu HR,Wu HY,Zhai HZ,Lu CY,Zhao X,Chen YQ,Zhou LL,Han JJ

    更新日期:2019-03-01 00:00:00

  • Osimertinib-induced severe interstitial lung disease: A case report.

    abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

    journal_title:Thoracic cancer



    authors: Fan M,Mo T,Shen L,Yang L

    更新日期:2019-07-01 00:00:00

  • Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

    abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

    更新日期:2018-01-01 00:00:00

  • A case of huge esophageal carcinosarcoma.

    abstract::Carcinosarcoma of the esophagus is a rare malignant neoplasm with both epithelial and mesenchymal (sarcomatous) components. We describe a case of a 72-year-old man with a huge esophageal tumor which could often have been considered inoperable. However, the patient underwent a curative resection and had a good prognosi...

    journal_title:Thoracic cancer



    authors: Hu M,Zhi XY,Sun KL

    更新日期:2011-11-01 00:00:00

  • miR-874 directly targets AQP3 to inhibit cell proliferation, mobility and EMT in non-small cell lung cancer.

    abstract:BACKGROUND:Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and high mortality. miR-874 has been determined to play a role in tumor suppression in several cancers. The purpose of our study was to detect the biological mechanisms of miR-874 and AQP3 in NSCLC. METHODS:CCK-8 and Trans...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Wang S,Wu Y,Yang S,Liu X,Lu Y,Liu F,Li G,Tian G

    更新日期:2020-06-01 00:00:00

  • Thoracoscopic completion right lower lobectomy after anteromedial basilar segmentectomy in early-stage lung cancer.

    abstract::This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

    journal_title:Thoracic cancer



    authors: Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

    更新日期:2019-05-01 00:00:00

  • Clinical experiences with molecular targeted therapy in lung cancer in China.

    abstract::In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审


    authors: Wang Y,Sun Y

    更新日期:2015-07-01 00:00:00

  • Mediastinal re-staging of non small-cell lung cancer.

    abstract::Selected patients with non small-cell lung cancer (NSCLC) with mediastinal lymph node involvement may have a survival benefit from surgical resection, particularly if mediastinal nodal down-staging occurs after induction therapy and complete resection is achieved with lobectomy. Accurate re-staging of the mediastinum ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审


    authors: Khoo KL

    更新日期:2012-05-01 00:00:00

  • Lung adenocarcinoma with anomalous bronchi and pulmonary veins preoperatively identified by computed tomography.

    abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

    journal_title:Thoracic cancer



    authors: Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

    更新日期:2016-09-01 00:00:00

  • The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.

    abstract:BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

    更新日期:2019-10-01 00:00:00

  • Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non-small cell lung cancer patients.

    abstract:BACKGROUND:Growing evidence indicates that high phosphoserine phosphatase (PSPH) expression is associated with tumor prognosis in many types of cancers. However, the role of PSPH in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the clinical significance of PSPH in NSCLC. M...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Liao L,Yu H,Ge M,Zhan Q,Huang R,Ji X,Liang X,Zhou X

    更新日期:2019-05-01 00:00:00

  • Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.

    abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

    journal_title:Thoracic cancer



    authors: Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

    更新日期:2017-11-01 00:00:00

  • Uniportal video-assisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center.

    abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

    更新日期:2021-01-06 00:00:00

  • Epidemiology of lung cancer in China.

    abstract:BACKGROUND:Lung cancer is the most common cancer and the leading cause of cancer death in China. Along with socioeconomic development, environmental problems have intensified and the burden of lung cancer continues to increase. METHODS:In this study, national cancer registry data was used for evaluating incidence, mor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Chen W,Zheng R,Zeng H,Zhang S

    更新日期:2015-03-01 00:00:00

  • EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

    abstract:BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Zhang L,Pradhan B,Guo L,Meng F,Zhong D

    更新日期:2020-02-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.

    abstract:BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Zhang L,Bai L,Liu X,Liu Y,Li S,Liu J,Zhang S,Yang C,Ren X,Cheng Y

    更新日期:2020-05-01 00:00:00

  • Right upper lobectomy in lung cancer with double aortic arch: A case report.

    abstract::Double aortic arch (DAA) is a rare congenital anomaly of the heart and aorta in which a vascular ring that surrounds the trachea and esophagus is formed. In most patients, respiratory distress and dysphagia develop in childhood, and asymptomatic adult patients are rarely known. Herein, we describe a patient with lung ...

    journal_title:Thoracic cancer



    authors: Kawamoto N,Okita R,Inokawa H,Hayashi M,Furukawa M,Okada M,Okabe K

    更新日期:2020-08-01 00:00:00

  • Tumor suppressive roles of eugenol in human lung cancer cells.

    abstract:BACKGROUND:Eugenol, a natural compound available in Syzigium aromaticum (cloves), is exploited for various medicinal applications. Eugenol induces apoptosis and functions as an anti-cancer drug in several types of tumors. We investigated the tumor suppressive role and potential mechanisms of eugenol in human lung cance...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Fangjun L,Zhijia Y

    更新日期:2018-01-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.

    abstract:BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

    更新日期:2017-07-01 00:00:00

  • Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer.

    abstract:BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Bi MM,Shang B,Wang Z,Chen G

    更新日期:2017-11-01 00:00:00

  • The 12th National Lung Cancer Academic Conference in China.

    abstract:BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Liu Y,Chen G,Qiu X,Chen J,Zhou Q

    更新日期:2012-08-01 00:00:00

  • Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

    abstract:BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio K

    更新日期:2017-01-01 00:00:00

  • Flap endonuclease-1 rs174538 G>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.

    abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Sang Y,Bo L,Gu H,Yang W,Chen Y

    更新日期:2017-05-01 00:00:00

  • Endobronchial ultrasound-guided transbronchial needle aspiration and its role in non-small cell lung cancer: Diagnostic impact and limitations.

    abstract::A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,评审


    authors: Dango S,Guenter J,Passlick B

    更新日期:2010-07-01 00:00:00

  • Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

    abstract:BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Zhang L,Zhao Q,Yuan F,Liu M

    更新日期:2020-06-01 00:00:00

  • Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β-catenin signaling pathway.

    abstract:BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章


    authors: Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

    更新日期:2019-01-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer



    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00